SCHEMBL20718128

SCHEMBL20718128

O=C1NC(=O)c2ccc3c4cc(Br)c5c6c(ccc(c7ccc1c2c73)c64)C(=O)NC5=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 1/20 0.40
▸ GSK3B P49841 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.38
▸ PPOX P50336 1/20 0.38
▸ WEE1 P30291 5/20 0.37
▸ CHEK1 O14757 4/20 0.37
▸ PARP1 P09874 5/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ RGS12 O14924 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ BRCA1 P38398 1/20 0.37
▸ MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19135976 0.86 NPSR1 (0.46) GSK3BNPSR1PPOXWEE1CHEK1
SCHEMBL7598198 0.80 PARP1 (0.41) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL29541 0.80 PARP1 (0.50) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL30606639 0.80 PARP1 (0.50) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL7601076 0.80 PARP1 (0.50) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL7598089 0.80 PARP1 (0.50) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL2854316 0.79 PARP1 (0.36) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL17243112 0.78 NPSR1 (0.42) BCL2GSK3BNPSR1PPOXWEE1
SCHEMBL19143852 0.78 GSK3B (0.47) GSK3BNPSR1PPOXWEE1CHEK1
SCHEMBL12744308 0.76 NPSR1 (0.44) BCL2GSK3BNPSR1PPOXWEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10818849-B2 Electron acceptors based on alpha-position substituted PDI for OPV solar cells THE UNIVERSITY OF CHICAGO (US) 2020-10-27 — — US disclosed
US-20190044074-A1 ELECTRON ACCEPTORS BASED ON ALPHA-POSITION SUBSTITUTED PDI FOR OPV SOLAR CELLS THE UNIVERSITY OF CHICAGO (US) 2019-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190044074-A1 ELECTRON ACCEPTORS BASED ON ALPHA-POSITION SUBSTITUTED PDI FOR OPV SOLAR CELLS PPOX, PPIE, PIN1 BCL2 1587/4885GSK3B 1254/4885NPSR1 4448/4885
US-10818849-B2 Electron acceptors based on alpha-position substituted PDI for OPV solar cells PPOX, PPIE, PIN1 BCL2 1587/4885GSK3B 1254/4885NPSR1 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback